United States Melanoma Diagnostic And Therapeutics Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The US melanoma diagnostics and therapeutics market spans diagnostic tools, including biopsy systems, pathology services, imaging technologies, and liquid biopsies, as well as therapeutic treatments ranging from surgical interventions to systemic drug therapies. As of 2025, the market has reached an estimated $7.37 billion in value, reflecting strong momentum following years of scientific breakthroughs in immuno-oncology. This growth trajectory underscores the critical intersection of rising disease burden and expanding treatment armamentaria.

• •Market size estimated at $7.37 billion in 2025 across diagnostics and therapeutics segments
• •Double-digit CAGR driven by rising melanoma incidence and treatment innovation
• •Broad scope covering screening, diagnostic confirmation, staging, and therapy across all melanoma stages

Several interconnected factors are accelerating market expansion. Rising incidence rates of melanoma, particularly among younger populations and those with high UV exposure, are increasing the patient pool requiring diagnosis and treatment. Advances in checkpoint inhibitor therapies and targeted BRAF/MEK inhibitors have transformed metastatic melanoma from a near-uniformly fatal diagnosis into a manageable chronic condition for many patients, expanding both treatment durations and market value.

• •Increasing melanoma incidence linked to UV exposure and changing dermatological patterns
• •FDA approvals of novel immunotherapies and combination regimens broadening treatment options
• •Reimbursement improvements and expanded insurance coverage for advanced diagnostics and therapies

The market divides into diagnostic and therapeutic segments, with therapeutics representing the larger share due to high drug costs and long-term treatment regimens. The diagnostic segment includes dermatopathology, molecular diagnostics, and imaging services, growing as precision medicine gains traction. Geographically, the US dominates the North American market due to its advanced healthcare infrastructure, high healthcare spending, and concentration of pharmaceutical R&D.

• •Therapeutics segment commands the majority of market revenue, led by immune checkpoint inhibitors and targeted therapies
• •Diagnostic segment expanding through adoption of molecular testing and AI-assisted pathology
• •United States accounts for the overwhelming majority of North American market share

What are the recent trends and outlook?

The market is positioned for sustained growth through 2030 and beyond, fueled by the pipeline of next-generation therapies including personalized cancer vaccines, adoptive cell therapies, and novel targeted agents. Diagnostic innovation, particularly in liquid biopsy, AI-powered dermatological imaging, and genomic profiling, will enable earlier detection and more precise treatment selection. The convergence of digital health platforms and at-home screening tools may further reshape how melanoma is identified and managed.

• •Pipeline of personalized vaccines and cell therapies expected to expand the addressable patient population
• •AI-driven diagnostic tools and liquid biopsies poised to improve early detection rates
• •Value-based care models and outcome-based pricing likely to influence market access and reimbursement